Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gynecologic 3

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1363Prostatic Neoplasms 1106Multiple Myeloma 872Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

pazopanib 1ixabepilone 1Gemcitabine 1Epothilones 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Recurrent Uterine Corpus Sarcoma × Clear all
NCT01168232 2019-08-08

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 10 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT00114218 2019-01-08

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

GOG Foundation

Phase 2 Completed
28 enrolled 7 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡